{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:36Z","timestamp":1792783416644,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The preparation of the manuscript and the journals\u2019 Rapid Service and Open Access fees, were funded by Eli Lilly and Company."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03161-3","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T02:54:01Z","timestamp":1742698441000},"page":"2403-2428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Evidence for Baricitinib in the Treatment of Rheumatoid Arthritis in Spain: A Systematic Literature Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Jos\u00e9","family":"Rosas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Belzunegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Hern\u00e1ndez-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-3957","authenticated-orcid":false,"given":"Itxaso","family":"Aguirregabiria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"D\u00edaz-Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"3161_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3015","volume":"362","author":"A Allen","year":"2018","unstructured":"Allen A, Carville S, McKenna F. Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance. BMJ. 2018;362: k3015. https:\/\/doi.org\/10.1136\/bmj.k3015.","journal-title":"BMJ"},{"key":"3161_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","volume":"32","author":"T Uhlig","year":"2014","unstructured":"Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 2014;32:841\u201351. https:\/\/doi.org\/10.1007\/s40273-014-0174-6.","journal-title":"Pharmacoeconomics"},{"key":"3161_CR3","doi-asserted-by":"publisher","first-page":"21551","DOI":"10.1038\/s41598-020-76511-6","volume":"10","author":"L Silva-Fern\u00e1ndez","year":"2020","unstructured":"Silva-Fern\u00e1ndez L, Mac\u00eda-Villa C, Seoane-Mato D, et al. The prevalence of rheumatoid arthritis in Spain. Sci Rep. 2020;10:21551. https:\/\/doi.org\/10.1038\/s41598-020-76511-6.","journal-title":"Sci Rep"},{"key":"3161_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/rheumatology\/41.1.88","volume":"41","author":"L Carmona","year":"2002","unstructured":"Carmona L, Villaverde V, Hern\u00e1ndez-Garc\u00eda C, Ballina J, Gabriel R, Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford). 2002;41:88\u201395. https:\/\/doi.org\/10.1093\/rheumatology\/41.1.88.","journal-title":"Rheumatology (Oxford)"},{"key":"3161_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR6","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10067-023-06654-0","volume":"42","author":"B Conley","year":"2023","unstructured":"Conley B, Bunzli S, Bullen J, et al. What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clin Rheumatol. 2023;42:2267\u201378. https:\/\/doi.org\/10.1007\/s10067-023-06654-0.","journal-title":"Clin Rheumatol"},{"key":"3161_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ. The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10:117\u201327. https:\/\/doi.org\/10.1177\/1759720X18776224.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3161_CR8","unstructured":"Olumiant Summary of Product Characteristics [Internet]. 2023 [cited 5 September 2023]. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed 5 Sept 2023."},{"key":"3161_CR9","unstructured":"Olumiant Prescribing Information [Internet]. 2018 [cited 5 September 2023]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf. Accessed 5 Sept 2023."},{"key":"3161_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094. (CORRECTION:AnnRheumDis.2017;76:1634.DOI:10.1136\/annrheumdis-2016-210094corr1).","journal-title":"Ann Rheum Dis"},{"key":"3161_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1507247.","journal-title":"N Engl J Med"},{"key":"3161_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506\u201317. https:\/\/doi.org\/10.1002\/art.39953.","journal-title":"Arthritis Rheumatol"},{"key":"3161_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Eng J Med. 2017;376:652\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1608345.","journal-title":"N Eng J Med"},{"key":"3161_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000898","volume":"5","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Schiff M, Tanaka Y, et al. Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open. 2019;5: e000898. https:\/\/doi.org\/10.1136\/rmdopen-2019-000898.","journal-title":"RMD Open"},{"key":"3161_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.1759","author":"R Caporali","year":"2022","unstructured":"Caporali R, Aletaha D, Sanmarti R, et al. POS0682. Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND following 6.9 years of treatment. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1759.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81:335\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1136\/ard.2009.109983","volume":"68","author":"T Sokka","year":"2009","unstructured":"Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009;68:1666\u201372. https:\/\/doi.org\/10.1136\/ard.2009.109983.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR18","doi-asserted-by":"publisher","first-page":"annrheumdis-202","DOI":"10.1136\/annrheumdis-2020-217520","volume":"79","author":"R Meisters","year":"2020","unstructured":"Meisters R, Putrik P, Ramiro S, et al. EULAR\/Eumusc.Net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Ann Rheum Dis. 2020;79:annrheumdis-2020. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217520.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR19","first-page":"4","volume":"1","author":"E Nolte","year":"2011","unstructured":"Nolte E, Newbould J, Conklin A. International variation in the usage of medicines: a review of the literature. Rand Health Q. 2011;1:4 (PMCID: PMC4945211).","journal-title":"Rand Health Q."},{"key":"3161_CR20","doi-asserted-by":"publisher","unstructured":"OECD.\u00a0Geographic variations in health care: what do we know and what can be done to improve health system performance? OECD Health Policy Studies, OECD Publishing, Paris. 2014.\u00a0https:\/\/doi.org\/10.1787\/9789264216594-en.","DOI":"10.1787\/9789264216594-en"},{"issue":"5","key":"3161_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.reumae.2012.06.008","volume":"8","author":"J Maese","year":"2012","unstructured":"Maese J, Garc\u00eda De Y\u00e9benes MJ, Carmona L, Hern\u00e1ndez-Garc\u00eda C, el Grupo de Estudio emAR II. Management of rheumatoid arthritis in spain (emAR II). Clinical characteristics of the patients. Reumatol Clin. 2012;8(5):236\u201342. https:\/\/doi.org\/10.1016\/j.reumae.2012.06.008.","journal-title":"Reumatol Clin."},{"issue":"10","key":"3161_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.reumae.2023.07.004","volume":"19","author":"A Balsa","year":"2023","unstructured":"Balsa A, Del Campo D, Fontecha P, Silva Fern\u00e1ndez L, et al. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis. Reumatol Clin. 2023;19(10):533\u201348. https:\/\/doi.org\/10.1016\/j.reumae.2023.07.004.","journal-title":"Reumatol Clin"},{"key":"3161_CR23","unstructured":"Higgins JPT, Chandler TJ, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 Cochrane, editor2023."},{"key":"3161_CR24","unstructured":"Strobe. Strobe Checklists 2023 [cited 5 September 2023]. Available from: https:\/\/www.strobe-statement.org\/checklists\/. Accessed 5 Sept 2023."},{"key":"3161_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"3161_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.reuma.2020.04.011","volume":"18","author":"J Rosas","year":"2022","unstructured":"Rosas J, Senabre-Gallego JM, Santos-Soler G, Antonio Bernal J, Pons BA. Efficacy and safety of baricitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic DMARDs and\/or biological DMARDs: data from a local registry. Reumatol Clin (Engl Ed). 2022;18:188\u20139. https:\/\/doi.org\/10.1016\/j.reuma.2020.04.011.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"3161_CR27","unstructured":"Rosas JC, Pons\u2011Bas A, Barber X, et al. P027. Supervivencia a largo plazo de baricitinib vs. tnfi como primer f\u00e1rmaco biol\u00f3gico en pacientes con artritis reumatoide en la pr\u00e1ctica cl\u00ednica: resultados de un registro local. Reumatol Clin. 2023; 19:118\u20139. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-19-num-sc2-sumario-X1699258X23X00S20?local=true. Accessed 7 Oct 2023."},{"issue":"Suppl. 1","key":"3161_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/annrheumdis-2022-eular.3949","volume":"81","author":"J Rosas","year":"2022","unstructured":"Rosas J, Pons A, Barber X, et al. POS0657 Survival of baricitinib vs. anti-tnf as the first biological drug in patients with rheumatoid arthritis, in clinical practice: results of a local registry. Ann Rheum Dis. 2022;81(Suppl. 1):600\u20131. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.3949.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1136\/annrheumdis-2020-eular.4982","volume":"79","author":"A Calvo Garcia","year":"2020","unstructured":"Calvo Garcia A, Garc\u00eda Casta\u00f1eda N, Valero C, et al. AB0334 Cost-efectiveness of JAK inhibitors in rheumatoid arthritis in the real-world practice. Ann Rheum Dis. 2020;79:1465\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.4982.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"3161_CR30","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2022-eular.2116","volume":"81","author":"H Codes-Mendez","year":"2022","unstructured":"Codes-Mendez H, Martinez-Molina C, Masip M, et al. AB0402 Therapeutic adherence and persistence of tofacitinib and baricitinib in rheumatoid arthritis patients in daily clinical practice. Ann Rheum Dis. 2022;81(Suppl. 1):1330. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.2116.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR31","unstructured":"Eg\u00fces Dubuc CA, de Diego Sola A, Alcorta Lorenzo N, et al. P027. Datos de vida real temprana en pacientes con artritis reumatoide tratados con baricitinib. Reumatol Clin. 2021; 17:67\u20138. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-17-num-sc2-sumario-X1699258X21X00C20. Accessed 6 Oct 2023."},{"key":"3161_CR32","unstructured":"Font Urgelles J. RC34. Persistencia de los inhibidores de la jak en artritis reumatoide en pr\u00e1ctica cl\u00ednica habitual. Reumatol Clin. 2022; 18:65. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-18-num-sc2-sumario-X1699258X22X00C20. Accessed 6 Oct 2023."},{"key":"3161_CR33","unstructured":"Frag\u00edo Gil JJ. P131. Evaluaci\u00f3n de la efectividad y seguridad de los inhibidores jak en el tratamiento de la artritis reumatoide en condiciones de vida real. Reumatol Clin. 2022; 18:211\u20132. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-18-num-sc2-sumario-X1699258X22X00C20. Accessed 7 Oct 2023."},{"key":"3161_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.reumae.2021.08.004","volume":"18","author":"R Gonz\u00e1lez Mazar\u00edo","year":"2022","unstructured":"Gonz\u00e1lez Mazar\u00edo R, Frag\u00edo Gil JJ, Ivorra Cort\u00e9s J, et al. Real-world effectiveness and safety of jak inhibitors in rheumatoid arthritis: a single-centre study. Reumatol Clin (Engl Ed). 2022;18:523\u201330. https:\/\/doi.org\/10.1016\/j.reumae.2021.08.004.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"3161_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7399\/fh.11586","volume":"45","author":"L Gonz\u00e1lez-Freire","year":"2021","unstructured":"Gonz\u00e1lez-Freire L, Gim\u00e9nez-Candela RM, Castro-Luaces S, Veiga-Villaverde AB, Crespo-Diz C. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice. Farm Hosp. 2021;45:165\u20139. https:\/\/doi.org\/10.7399\/fh.11586.","journal-title":"Farm Hosp"},{"key":"3161_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-021-00423-8","volume":"9","author":"B Hern\u00e1ndez-Cruz","year":"2022","unstructured":"Hern\u00e1ndez-Cruz B, Rosas J, D\u00edaz-Torn\u00e9 C, et al. Real-world treatment patterns and clinical outcomes of baricitinib in rheumatoid arthritis patients in Spain: results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study). Rheumatol Ther. 2022;9:589\u2013608. https:\/\/doi.org\/10.1007\/s40744-021-00423-8. (CORRECTION: Rheumatol Ther. 2022; 9:1245\u20136. 10.1007\/s40744-022-00463-8).","journal-title":"Rheumatol Ther."},{"key":"3161_CR37","first-page":"224","volume":"19","author":"NA Lorenzo","year":"2023","unstructured":"Lorenzo NA, Eg\u00fces Dubuc CA, L\u00f3pez Dom\u00ednguez LM, El Ouariachi LE, De Diego SA, Jaimes JAV. Eventos cardiovasculares mayores, trombosis e infecci\u00f3n por virus de herpes z\u00f3ster en pacientes con artritis reumatoide tratados con baricitinib. Reumatol Clin. 2023;19:224\u20135.","journal-title":"Reumatol Clin"},{"key":"3161_CR38","first-page":"312","volume":"17","author":"J Loricera Garc\u00eda","year":"2021","unstructured":"Loricera Garc\u00eda J, Mart\u00ednez-L\u00f3pez D, Gonz\u00e1lez-Maz\u00f3n I, Rueda-Gotor J, Corrales-Mart\u00ednez A, Mart\u00ednez-Onand\u00eda \u00c1. RC05. Efectividad y seguridad del baricitinib en pacientes con artritis reumatoide tratados previamente con tofacitinib. Reumatol Clin. 2021;17:312\u20133.","journal-title":"Reumatol Clin."},{"key":"3161_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.55563\/clinexprheumatol\/cbanza","volume":"39","author":"M Retuerto","year":"2021","unstructured":"Retuerto M, Trujillo E, Valero C, et al. Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study. Clin Exp Rheumatol. 2021;39:453\u20135. https:\/\/doi.org\/10.55563\/clinexprheumatol\/cbanza.","journal-title":"Clin Exp Rheumatol"},{"key":"3161_CR40","unstructured":"Sarabia de Ardanaz L, P\u00e9rez Galan MJ, Mart\u00edn Mart\u00edn I, Caliz Caliz y. an\u00e1lisis de la eficacia y supervivencia de baricitinib en pr\u00e1ctica cl\u00ednica real. Reumatol Clin. 2022; 18:65\u20136. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-18-num-sc2-sumario-X1699258X22X00C20. Accessed 6 Oct 2023."},{"key":"3161_CR41","unstructured":"Valera Ribera C, Flores Fern\u00e1ndez E, And\u00fajar Brazal P, et al. RC56. persistencia de baricitinib a dosis 2 mg en vida real: influencia del peso corporal. estudio multic\u00e9ntrico. Reumatol Clin. 2022; 18:82\u20133. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-18-num-sc2-sumario-X1699258X22X00C20. Accessed 7 Oct 2023."},{"issue":"Suppl. 2","key":"3161_CR42","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1136\/annrheumdis-2019-eular.5885","volume":"78","author":"RJG Velez","year":"2019","unstructured":"Velez RJG, Cros CA, Roman AR, et al. AB0324 Pain improvement in rheumatoid arthritis patients treated with baricitinib: results of a prospective study. Ann Rheum Dis. 2019;78(Suppl. 2):1620. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.5885.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"3161_CR43","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1136\/annrheumdis-2020-eular.6615","volume":"79","author":"ML Velloso-Feijoo","year":"2020","unstructured":"Velloso-Feijoo ML, Boza NC, P\u00e9rez MJ. AB0363 Safety of jak inhibitors in patients with arthritis rheumatoid under real-life conditions. Ann Rheum Dis. 2020;79(Suppl. 1):1482. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.6615.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR44","unstructured":"Charca Benavente LC, Sanmart\u00edn JJ, Torrijo NC, et al. P385. Experiencia y seguridad con inhibidores de janus kinasa en un hospital terciario. Reumatol Clin. 2023; 19:434\u20135. Available from: https:\/\/www.reumatologiaclinica.org\/es-vol-19-num-sc2-sumario-X1699258X23X00S20?local=true. Accessed 9 Oct 2023."},{"key":"3161_CR45","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.rdc.2009.10.008","volume":"35","author":"T Pincus","year":"2009","unstructured":"Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin N Am. 2009;35:773\u20138. https:\/\/doi.org\/10.1016\/j.rdc.2009.10.008. (viii).","journal-title":"Rheum Dis Clin N Am."},{"key":"3161_CR46","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s40744-023-00591-9","volume":"10","author":"B Hern\u00e1ndez-Cruz","year":"2023","unstructured":"Hern\u00e1ndez-Cruz B, Kiltz U, Avouac J, et al. Systematic literature review of real-world evidence on baricitinib for the treatment of rheumatoid arthritis. Rheumatol Ther. 2023;10:1417\u201357. https:\/\/doi.org\/10.1007\/s40744-023-00591-9.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"3161_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Thein D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53: 151979. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979.","journal-title":"Semin Arthritis Rheum"},{"key":"3161_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2024.100178","volume":"6","author":"S Parisi","year":"2024","unstructured":"Parisi S, Andrea B, Chiara DM, et al. Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients. Curr Res Pharmacol Drug Discov. 2024;6: 100178. https:\/\/doi.org\/10.1016\/j.crphar.2024.100178.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"Suppl. 1","key":"3161_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/annrheumdis-2022-eular.3989","volume":"81","author":"S Bayat","year":"2022","unstructured":"Bayat S, Tascilar K, Bohr D, et al. POS0699 Similar efficacy and drug survival rates of baricitinib monotherapy and baricitinib\/methotrexate combination therapy in real-life treatment of rheumatoid arthritis-results from a prospective cohort of baricitinib-treated patients. Ann Rheum Dis. 2022;81(Suppl. 1):629. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.3989.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR51","doi-asserted-by":"publisher","first-page":"1176613","DOI":"10.3389\/fmed.2023.1176613","volume":"10","author":"C Baldi","year":"2023","unstructured":"Baldi C, Berlengiero V, Falsetti P, et al. Baricitinib retention rate: \u2018real-life\u2019 data from a mono-centric cohort of patients affected by rheumatoid arthritis. Front Med (Lausanne). 2023;10:1176613. https:\/\/doi.org\/10.3389\/fmed.2023.1176613.","journal-title":"Front Med (Lausanne)"},{"key":"3161_CR52","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1093\/rheumatology\/kead074","volume":"62","author":"CJ Edwards","year":"2023","unstructured":"Edwards CJ, Mount J, Meeks A, et al. Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data. Rheumatology (Oxford). 2023;62:3400\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kead074.","journal-title":"Rheumatology (Oxford)"},{"key":"3161_CR53","doi-asserted-by":"publisher","unstructured":"Alten R, Burmester GR, Matucci-Cerinic M, et al., editors. Time to discontinuation and effectiveness with baricitinib in rheumatoid arthritis: 12-month European data from a multinational, prospective, observational study [abstract]. Arthritis Rheumatol. 2022; 74(S9) https:\/\/doi.org\/10.1002\/art.42355","DOI":"10.1002\/art.42355"},{"key":"3161_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","volume":"14","author":"C Martinez-Molina","year":"2024","unstructured":"Martinez-Molina C, Gich I, Diaz-Torn\u00e9 C, et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14:172. https:\/\/doi.org\/10.1038\/s41598-023-50379-8.","journal-title":"Sci Rep"},{"issue":"2","key":"3161_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004291","volume":"10","author":"CJ van de Laar","year":"2024","unstructured":"van de Laar CJ, Oude Voshaar MAH, Ten Klooster P, et al. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. RMD Open. 2024;10(2): e004291. https:\/\/doi.org\/10.1136\/rmdopen-2024-004291.","journal-title":"RMD Open"},{"issue":"4","key":"3161_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA, et al. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u201cJAK-pot\u201d study). Ann Rheum Dis. 2024;83(4):421\u20138. https:\/\/doi.org\/10.1136\/ard-2023-224670.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"3161_CR57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31138\/mjr.31.1.129","volume":"31","author":"K Thomas","year":"2020","unstructured":"Thomas K, Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol. 2020;31(Suppl. 1):129\u201336. https:\/\/doi.org\/10.31138\/mjr.31.1.129.","journal-title":"Mediterr J Rheumatol."},{"key":"3161_CR58","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","volume":"95","author":"F Wang","year":"2020","unstructured":"Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95:1404\u201319. https:\/\/doi.org\/10.1016\/j.mayocp.2020.01.039.","journal-title":"Mayo Clin Proc"},{"key":"3161_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74:333\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206478.","journal-title":"Ann Rheum Dis"},{"key":"3161_CR60","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79:1290\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216852.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3161_CR61","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"3161_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6: e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03161-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03161-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03161-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:51:13Z","timestamp":1744858273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03161-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3161"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03161-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jos\u00e9 Rosas reports consultant fees and\/or honoraria and\/or travel support from: AbbVie, AstraZeneca, Galapagos, GSK, Lilly, Novartis and UCB. Joaqu\u00edn Belzunegui and Blanca Hernandez-Cruz have no conflicts to declare. Itxaso Aguirregabiria, Sebasti\u00e1n Moyano, Amelia Cobo and Silvia D\u00edaz-Cerezo, are employees and minor shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}